Search

Introduction. Even if for a long time patients with IBD were considered malnourished and underweight, there is an important subgroup suffering from obesity and overweight. Aim. The aim of this study was to assess how obesity influences the response to treatment and the evolution of IBD. Materials and Methods. We perform a retrospective observational study including102 patients divided into 23 patients with obesity (BMI>30kg/m2)-22.5%, 41 overweight patients (BMI> 25kg/m2)-40.1%, 33 normal weight patients (BMI 18.5-25 kg/m2)- 32% and 5 underweight pacients (BMI <18.5)- 4.9% out of 177 patients with IBD admitted in our center during 1st Jan 2022-31 Dec 2022. Because of lack of data 75 patients were excluded from this study. We decided to organise the patients in 2 groups: G1- obese and overweight and G2- normal weight patients. Results: There were 64.7% CD patients (24.2% obese, 39.4% overweight) and 35.3% UC patients(a lower percentage of obese patients 19.4% but similar for overweight patients 41.7%). Also, obesity and overweight was more frequently identified at male patients than female patients(70.8%vs 48.6%) and it seems to be more common for people over 40 years old(67.1% of our patients). CD patients from G1 had a lower prevalence of penetrating disease 4.7% vs 21.2% from G2 patients, but higher rates of perianal disease(26.2% vs 12.1%). Obesity seems not affect the extension of UC disease as G1 and G2 patients present the most common form- pancolitis 45.5% and 61.5%. Anti-TNF medication was preferred for both categories(48.4% Infliximab and 26.5% Adalimumab for G1vs 42.4% and 24.2% for G2), with the mention that 46.9% of G1 patients vs 21.2% of G2 patients required the optimization of the dose of biological treatment, but with similar rates of switch with another biosimilar. The prior surgery was comparable for both groups(28.1% G1 vs 21.2% G2), with a preference for laparoscopic surgery 54.1% vs 35% for the last category(G2) and also a lower risk of postoperative complications (3% vs 20%). Conclusion: Patients with IBD present rates similar to the general population of obesity prevalence. Also, obesity seems to be involved in maintaining a chronic proinflammatory status of these patients, with a poor response to therapies that are not weight-based and intravenously administered, frequently requiring to escalate the treatment dose and a more difficult laparoscopic access for surgery with a higher risk of developing postoperative complications. [ABSTRACT FROM AUTHOR]

Introduction. Hereditary colorectal cancer (HCRC) syndromes represent a relatively diverse group of disorders that exhibit different patterns of inheritance. We aim to create the first registry of this type for this category of patients in order for them to have access to better healthcare and to give them a new perspective Keyword: colorectal cancer, hereditary syndromes, cancer registry Materials and Methods. We started collecting data since August 2021. We made an extensive examination consisting of personal infromation and important clinical data. All patients introduced in the study had lower and upper GI examinations performed, and also CT exams when indicated by guidelines. For Lynch Syndrome we used the Amsterdam and Bethesda criteria, while for familial adenomatous polyposis syndrome we combined the colonoscopy results with family history. We also collected family information in order to be able to perform screening testing for them depending on their respective syndrome. Results. We managed to introduce 26 patients that have either a genetic, histological or clinical diagnosis. Out of these, some are only family members that haven't been genetically tested and aren't diagnosed yet, but still have to be followed. We have 22 index patients, and are currently actively following other family members at high risk. We have 6 Lynch Syndrome families, 2 Peutz-Jeghers families, 3 Attenuated FAP Syndrome families, 2 MAP families, 7 FAP families and one Juvenile polyposis syndrome family with a sex distribution male to female of 9:17, (34.61% male, 65.39% female). Both patients with MAP have had genetic testing done, and also the Juvenile polyposis patient. Currently, family members are being introduced into the study in order to perform screening examinations according to guidelines and create an efficient timetable that can help prevent complications and diagnosis of advanced tumours. Conclusion. While challenging, it is clear that there is an urgent need for an electronic registry in order to offer this category of pacients a better life expectancy and a better quality of life. [ABSTRACT FROM AUTHOR]